Health
AstraZeneca to Invest $1.5 Billion in New Singapore Manufacturing Plant
AstraZeneca has announced plans to construct a $1.5 billion manufacturing facility in Singapore, focusing on the production of antibody-drug conjugates (ADCs). The facility, which will be the company's first end-to-end ADC production site, is supported by the Singapore Economic Development Board. ADCs are designed to target tumor